Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:application |
applied to the scalp
|
| gptkbp:approves |
gptkb:1988
gptkb:FDA |
| gptkbp:available_on |
gptkb:pharmaceuticals
|
| gptkbp:brand |
gptkb:Minoxidil
|
| gptkbp:clinical_trial |
showed effectiveness
|
| gptkbp:clinical_use |
treatment of female pattern hair loss
treatment of male pattern baldness |
| gptkbp:contraindication |
pregnancy
breastfeeding allergy to minoxidil |
| gptkbp:dosage_form |
gptkb:liquid
spray twice daily |
| gptkbp:duration |
up to 1 year
at least 4 months |
| gptkbp:financial_support |
do not exceed recommended dosage
consult doctor if side effects occur |
| gptkbp:formulation |
foam
topical solution |
| gptkbp:healthcare |
topical
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rogaine
|
| gptkbp:ingredients |
gptkb:minoxidil
|
| gptkbp:invention |
patented
|
| gptkbp:manufacturer |
gptkb:Johnson_&_Johnson
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:Asia gptkb:North_America topical treatment for androgenetic alopecia |
| gptkbp:mechanism_of_action |
vasodilator
|
| gptkbp:patient_population |
adults
adolescents |
| gptkbp:previous_name |
gptkb:minoxidil
|
| gptkbp:provides_guidance_on |
recommended for androgenetic alopecia
|
| gptkbp:research |
demonstrated efficacy
demonstrated safety adverse effects monitoring long-term use effects |
| gptkbp:shelf_life |
2 years
|
| gptkbp:side_effect |
dizziness
weight gain rapid heartbeat scalp irritation unwanted facial hair growth |
| gptkbp:storage |
room temperature
|
| gptkbp:strength |
2% solution
5% foam 5% solution |
| gptkbp:target_audience |
gptkb:women
men |
| gptkbp:treatment |
hair regrowth
improved hair density improved scalp coverage slowed hair loss |
| gptkbp:used_for |
hair loss
|
| gptkbp:bfsParent |
gptkb:Upjohn
|
| gptkbp:bfsLayer |
5
|